INTREPID

  • What's involved: A randomised, double blind, placebo controlled, multicenter, dose ranging, Phase 2 study, to evaluate the safety and efficacy of EDP-305 in subjects with primary biliary cholangitis (PBC) with or without an inadequate response to ursodeoxycholic acid (UDCA).
  • Take part: Open
  • Principal Investigator: Professor Stephen Ryder
Research Theme | Gastrointestinal & Liver | Open Trials

A randomised, double blind, placebo controlled, multicenter, dose ranging, Phase 2 study, to evaluate the safety and efficacy of EDP-305 in subjects with primary biliary cholangitis (PBC) with or without an inadequate response to ursodeoxycholic acid (UDCA).

What's involved

A randomised, double blind, placebo controlled, multicenter, dose ranging, Phase 2 study, to evaluate the safety and efficacy of EDP-305 in subjects with primary biliary cholangitis (PBC) with or without an inadequate response to ursodeoxycholic acid (UDCA).

Principal Investigator

Professor Stephen Ryder

Take part

Open
Back to all trials

Contact Us

NIHR Biomedical Research Centre: Nottingham
Research & Innovation
D Floor (via South Block)
Nottingham University Hospitals NHS Trust
Queen’s Medical Centre
Derby Road
Nottingham
NG7 2UH

Telephone: 0115 924 9924

Director: Professor Ian Hall

Hosted by

Nottingham University Hospitals Logo

Nottingham University Hospitals Logo

We are a partnership between Nottingham University Hospitals NHS Trust and the University of Nottingham, supported by NHS and academic partners in Nottingham and across the East Midlands.

Website by Volute